EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Biomarker for Antimitochondrial Antibodies in Systemic Sclerosis Patients

Elvira Favoino iD, Silvia De Santis iD, Vasiliki Liakouli iD, Giovanna Barbuti iD, Sabina Piccolo, Ada Corrado iD, Marta Vomero iD, Luca Navarini iD, Marcella Prete iD, Patrizia Leone iD, Vito Racanelli iD, Rosa Daniela Grembiale iD und 5 weitere

Journal of Immunology Research · 2026-01 · 2026 (1)

DOI: 10.1155/jimr/2726162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunology Research, online erschienen am 05.07.2026. Verfasst von Elvira Favoino und 16 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cellular and Molecular Immunology, Department of Interdisciplinary Medicine, University of Bari Medical School, Bari, Italy, uniba.it. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Autoantibodies, Mitochondria. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry for Universities and Research (MUR), European Union-NextGeneration EU, Universita degli Studi di Bari Aldo Moro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We previously identified, using a synthetic peptide, namely peptide 4.33 (p4.33), a subgroup of anti‐CENP‐A antibodies (Abs) recognizing an epitope shared between the CENP‐A region spanning amino acids 1‐17 (Ap1‐17) and the E2 component of the mitochondrial pyruvate dehydrogenase complex (PDC‐E2), the major mitochondrial target autoantigen in primary biliary cholangitis (PBC). Here, we evaluated whether anti‐p4.33 Ab positivity may be associates with a higher prevalence of antimitochondrial Ab (AMA) in systemic sclerosis (SSc) patients.

Methods

Serum samples from 145 anti‐CENP pos SSc patients were tested for anti‐CENP‐A, ‐Ap1‐17, and ‐p4.33 Abs by ELISA. Subsequently, 32 anti‐Ap1‐17 pos /p4.33 pos and 32 anti‐Ap1‐17 pos /p4.33 neg were randomly selected and tested for AMA by immunoblotting.

Results

Of 145 anti‐CENP pos patients, 128 (88.2%) were anti‐CENP‐A pos patients, of which 103 (80.5%) were positive for anti‐Ap1‐17 Abs and 66 (51.6%) were positive for anti‐p4.33 Abs. Of 32 selected anti‐Ap1‐17 pos /p4.33 pos patients, 15 (46.9%) were also positive for AMA targeting PDC‐E2 and/or the branched chain 2‐oxo acid dehydrogenase complex (BCOADC‐E2). In the Ap1‐17 pos /p4.33 neg group, AMA were detected in only two patients (6.25%). AMA positivity was statistically different between groups. Anti‐p4.33 Ab levels were directly associated more than anti‐Ap1‐17 Ab levels with AMA levels. Sequence homology analyses demonstrated that anti‐p4.33 Abs recognize an epitope (kPsaP) strongly overlapping with those of Ap1‐17, PDC‐E2, and BCOADC‐E2, also expressed by viral and bacterial proteins.

Conclusions

Anti‐p4.33 Abs may be a useful biomarker to define a subset of SSc patients with a higher prevalence of AMA. Our findings also support the hypothesis that pathogens can trigger autoimmunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicAutoantibodiesMitochondriaHumansBiomarkersFemaleMiddle AgedAdultAutoantigensMaleCentromere Protein AAgedEpitopesLiver Cirrhosis, Biliary

Stichwörter der Autor:innen

anti-CENP-A antibodiesantimitochondrial antibodiesbiomarker riskprimary biliary cholangitissystemic sclerosis

Substanzen

AutoantibodiesBiomarkersAutoantigensCentromere Protein AEpitopes

Autor:innen und Institutionen

  • Laboratory of Cellular and Molecular Immunology, Department of Interdisciplinary Medicine, University of Bari Medical School, Bari, Italy, uniba.it.
  • Rheumatology Section, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, unina2.it.
  • Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy, uniba.it.
  • Rheumatology Unit, Department of Medical and Surgery Sciences, University of Foggia, Foggia, Italy, unifg.it.
  • Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Bio-Medico, Via Álvaro del Portillo 200, Rome, 00128, Italy, unicampus.it.
  • Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome "Campus Biomedico", Rome, Italy, unicampus.it.

ORCID-Profile: Elvira Favoino, Silvia De Santis, Vasiliki Liakouli, Giovanna Barbuti, Ada Corrado, Marta Vomero, Luca Navarini, Marcella Prete, Patrizia Leone, Vito Racanelli, Rosa Daniela Grembiale, Piero Ruscitti, Francesco Paolo Cantatore, Francesco Ciccia, Roberto Giacomelli, Federico Perosa

Förderung

  • Ministry for Universities and Research (MUR)
  • European Union-NextGeneration EU
  • Universita degli Studi di Bari Aldo Moro
  • CRUI-CARE

Zitieren

APA

Favoino, E., Santis, S., Liakouli, V., Barbuti, G., Piccolo, S., Corrado, A., Vomero, M., Navarini, L., Prete, M., Leone, P., Racanelli, V., Grembiale, R. D., Ruscitti, P., Cantatore, F. P., Ciccia, F., Giacomelli, R., & Perosa, F. (2026). Novel Biomarker for Antimitochondrial Antibodies in Systemic Sclerosis Patients. Journal of Immunology Research, 2026(1). https://doi.org/10.1155/jimr/2726162

Vancouver

Favoino E, Santis S, Liakouli V, Barbuti G, Piccolo S, Corrado A, et al. Novel Biomarker for Antimitochondrial Antibodies in Systemic Sclerosis Patients. Journal of Immunology Research. 2026;2026(1). doi:10.1155/jimr/2726162

BibTeX
@article{Favoino2026,
  author = {Favoino, Elvira and Santis, Silvia De and Liakouli, Vasiliki and Barbuti, Giovanna and Piccolo, Sabina and Corrado, Ada and Vomero, Marta and Navarini, Luca and Prete, Marcella and Leone, Patrizia and Racanelli, Vito and Grembiale, Rosa Daniela and Ruscitti, Piero and Cantatore, Francesco Paolo and Ciccia, Francesco and Giacomelli, Roberto and Perosa, Federico},
  title = {Novel Biomarker for Antimitochondrial Antibodies in Systemic Sclerosis Patients},
  journal = {Journal of Immunology Research},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/jimr/2726162}
}
Kostenlos starten →